Short Interest in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Expands By 34.2%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 5,100 shares, a growth of 34.2% from the July 15th total of 3,800 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 12,400 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

CLGN has been the subject of several research analyst reports. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a report on Thursday, May 30th.

Hedge Funds Weigh In On CollPlant Biotechnologies

Hedge funds have recently added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. raised its holdings in CollPlant Biotechnologies by 11.3% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 50,150 shares of the company’s stock worth $320,000 after purchasing an additional 5,100 shares during the last quarter. Villere ST Denis J & Co. LLC grew its position in shares of CollPlant Biotechnologies by 1.6% during the 1st quarter. Villere ST Denis J & Co. LLC now owns 366,967 shares of the company’s stock worth $1,963,000 after buying an additional 5,674 shares during the period. Finally, Pinnacle Associates Ltd. raised its stake in shares of CollPlant Biotechnologies by 13.3% during the first quarter. Pinnacle Associates Ltd. now owns 530,455 shares of the company’s stock worth $2,838,000 after buying an additional 62,346 shares during the last quarter. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

Shares of CLGN stock traded up $0.11 during trading hours on Thursday, reaching $4.60. 1,513 shares of the company were exchanged, compared to its average volume of 9,700. CollPlant Biotechnologies has a fifty-two week low of $4.15 and a fifty-two week high of $7.88. The stock’s fifty day moving average is $4.88 and its two-hundred day moving average is $5.30. The company has a market cap of $52.68 million, a price-to-earnings ratio of -6.76 and a beta of 0.24.

CollPlant Biotechnologies (NASDAQ:CLGN) last posted its quarterly earnings data on Wednesday, May 29th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.60 million. CollPlant Biotechnologies had a negative return on equity of 24.74% and a negative net margin of 70.58%. On average, research analysts anticipate that CollPlant Biotechnologies will post -1.46 earnings per share for the current year.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.